CYRX Form 144: Insider Plans $87K Share Sale After Recent Disposals
Rhea-AI Filing Summary
CryoPort, Inc. (CYRX) – Form 144 Filing Overview
An insider, identified in the filing as Ramkumar Mandalam, has filed a Form 144 indicating his intent to sell 13,321 common shares of CryoPort through broker Morgan Stanley Smith Barney on or about 24 June 2025. Based on the stated aggregate market value of $87,385.76, the planned transaction equates to an implied price of roughly $6.56 per share.
The filing also discloses that Mandalam has already disposed of 16,334 shares in four separate transactions between 9 June 2025 and 13 June 2025, generating gross proceeds of $115,000 +. Combining past and proposed sales, total recent dispositions amount to 29,655 shares.
Relative to CryoPort’s 50.14 million shares outstanding, the proposed sale represents approximately 0.03 % of total shares, and the cumulative three-month sales represent about 0.06 %, suggesting limited dilution risk. The shares to be sold were acquired via a same-day stock-option exercise paid in cash. No adverse, non-public information is asserted by the filer, as required under Rule 144.
For investors, Form 144 signals potential insider sentiment changes, but the modest size versus the share count indicates a low direct share-supply impact. Nevertheless, repeated sales within a short window may warrant monitoring for future filings.
Positive
- None.
Negative
- Insider selling concentration: Planned sale of 13,321 shares plus 16,334 shares already sold in June may raise short-term sentiment concerns despite representing only 0.06% of shares outstanding.
Insights
TL;DR Insider plans to sell 13,321 CYRX shares; total recent sales 29,655 shares, just 0.06% of float—impact likely modest.
The Form 144 reveals Dr. Ramkumar Mandalam’s intent to sell an additional 13,321 shares following a series of four sales earlier in June. Although insider selling can sometimes hint at weakening confidence, the absolute amount is immaterial relative to CryoPort’s 50 million-plus shares outstanding. The shares stem from an option exercise, a routine liquidity event for executives. From a liquidity standpoint, the transaction adds negligible supply and is unlikely to pressure the stock. However, the clustering of sales within two weeks could attract short-term attention from momentum traders. No financial performance data or company-specific catalysts are disclosed, so valuation or earnings outlooks remain unchanged.
